{"id":"W4385705955","doi":"10.1097/01.hs9.0000971156.02746.02","title":"P1065: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANTI–PD-1–NAIVE RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Jewish General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Internal medicine; Refractory (planetary science); Oncology; Lymphoma; Cohort; Phases of clinical research; Cancer; Chemotherapy; Gastroenterology; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003376508,0.000925687,0.001821791,0.0006225511,0.0003509819,0.001304184,0.0009640134,0.001156465,0.007246266],"category_scores_gemma":[0.002311549,0.0003627967,0.002315998,0.0008818196,0.0002999279,0.000976256,0.0004113843,0.001806195,0.001813009],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001054944,"about_ca_system_score_gemma":0.001322558,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001817268,"about_ca_topic_score_gemma":0.005231432,"domain_scores_codex":[0.9989141,0.0004088944,0.0001369007,0.0001292545,0.0002968218,0.0001139127],"domain_scores_gemma":[0.997972,0.0004557934,0.0006766433,0.0001229064,0.0003875155,0.0003852203],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2657873,0.009897491,0.04256174,0.007103291,0.01253192,0.000954922,0.0003445056,0.003784726,0.04152171,0.0003580172,0.1086356,0.5065188],"study_design_scores_gemma":[0.2642185,0.1644731,0.3519167,0.001324909,0.02024697,0.00355639,0.0002395513,0.002632699,0.01327109,0.0008141682,0.1770657,0.0002401427],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7246983,0.08988556,0.004912559,0.008036679,0.002188634,0.00774311,0.1278942,0.0009312464,0.03370966],"genre_scores_gemma":[0.7873368,0.028201,0.009480709,0.01098984,0.00176203,0.004937771,0.1443592,0.0002792762,0.01265334],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007246266,"threshold_uncertainty_score":0.02424115,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03312883533950021,"score_gpt":0.3242228969276194,"score_spread":0.2910940615881191,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}